Published in Vaccine Weekly, September 18th, 2002
Results are reported in Canadian dollars with a June 30, 2002, rate of $1.00 Canadian equaling US$0.66.
Financial results for the 6 months ended June 30, 2002, reflect a consolidated net loss from operations of $15.4 million or $0.34 per share compared with $22.9 million or $0.45 per share, for the same period in 2001. The decreased loss in 2002 is due to an $8.6 million reduction in gross research and development expenditures offset by $1.1 million in market development costs.
Contract research and development revenues for the 6 months...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.